|Bid||0.7900 x N/A|
|Ask||0.7900 x N/A|
|Day's Range||0.7000 - 0.8000|
|52 Week Range||0.2400 - 0.9900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MindMed Collaborating On Study Comparing Effects Induced By LSD and Psilocybin Under Exclusive License Agreement With University Hospital Basel Liechti Lab BASEL, Switzerland, Sept. 24, 2020 /CNW/ -- Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines announces, at the request of IIROC on behalf of the NEO Exchange, that MindMed's management is unaware of any material change in MindMed's operations that would account for the recent increase in market activity.
Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ").